Epithelial Mesenchymal Transition and Pancreatic Tumor Initiating CD44+/EpCAM+ Cells Are Inhibited by γ-Secretase Inhibitor IX

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Palagani, Vindhya ^a   El Khatib, Mona ^a   Kossatz, Uta ^a   Bozko, Przemyslaw ^a   Müller, Martin R ^a   Manns, Michael P ^b   Krech, Till ^b   Malek, Nisar P ^a   Plentz, Ruben R ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPITHELIAL CELL ADHESION MOLECULE; GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE INHIBITOR IX; HERMES ANTIGEN; NOTCH RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC TUMOR INITIATING CELL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ADENOCARCINOMA; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIGENS, CD44; ANTIGENS, NEOPLASM; APOPTOSIS; BIOLOGICAL ASSAY; CELL ADHESION MOLECULES; CELL COUNT; CELL LINE, TUMOR; CELL MOVEMENT; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; WOUND HEALING;

EID: 84867687369     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046514     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics. Cancer J Clin 60: 277-300.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M, (2011) Pancreatic cancer Lancet 378: 607-20.
3. Hidalgo M, (2010) Pancreatic cancer: an overview. N Engl J Med 362: 1605-17.
4. Stathis A, Moore MJ, (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nature Reviews Clinical Oncology 7: 163-172.
5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-25.
6. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, et al. (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25: 579-86.
7. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA, (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-49.
8. Hansel DE, Kern SE, Hruban RH, (2003) Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 4: 237-56.
9. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, et al. (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57: 1731-4.
10. Cano CE, Motoo Y, Iovanna JL, (2010) Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. ScientificWorldJournal 10: 1947-57.
11. Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, et al. (2004) N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 10: 4125-33.
12. Maeda M, Johnson KR, Wheelock MJ, (2005) Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchymal transition. J Cell Sci 118: 873-87.
13. Jing Y, Han Z, Zhang S, Liu Y, Wei L, (2011) Epithelial-Mesenchymal Transition in tumor microenvironment. Cell Biosci 31: 29.
14. Rachagani S, Senapati S, Chakraborty S, Ponnusamy MP, Kumar S, et al. (2011) Activated KrasG(1)(2)D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer 104: 1038-48.
15. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-8.
16. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-23.
17. Hermann PC, Huber SL, Heeschen C, (2008) Metastatic cancer stem cells: a new target for anti-cancer therapy? Cell Cycle 7: 188-93.
18. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC, (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-806.
19. Ischenko I, Seeliger H, Jauch KW, Bruns CJ, (2009) Metastatic activity and chemotherapy resistance in human pancreatic cancer-influence of cancer stem cells. Surgery 146: 430-4.
20. Lonardo E, Hermann PC, Heeschen C, (2010) Pancreatic cancer stem cells- update and future perspectives. Mol Oncol 4: 431-42.
21. Yin T, Wei H, Gou S, Shi P, Yang Z, et al. (2011) Cancer stem-like cells enriched in panc-1 spheres possess increased migration ability and resistance to gemcitabine. Int J Mol Sci 12: 1595-604.
22. Bednar F, Simeone DM, (2011) Pancreatic cancer stem cell biology and its therapeutic implications. J Gastroenterol [Epub ahead of print].
23. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-7.
24. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, et al. (2007) Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 67: 2187-96.
25. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, et al. (2011) c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target. Gastroenterology 141: 2218-2227.
26. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, et al. (2009) Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137: 1102-13.
27. Koch U, Radtke F, (2010) Notch signaling in solid tumors. Curr Top Dev Biol 92: 411-55.
28. Artavanis-Tsakonas S, Rand MD, Lake RJ, (1999) Notch signaling: cell fate control and signal integration in development. Science 284: 770-6.
29. Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, et al. (2009) Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 136: 1741-9 e6.
30. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, et al. (2009) Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 15: 2291-301.
31. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, et al. (2003) Notch mediated TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3: 565-76.
32. Buchler P, Gazdhar A, Schubert M, Giese N, Reber HA, et al. (2005) The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg 242: 791-800.
33. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, et al. (2006) Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 5: 483-93.
34. Mazur PK, Einwachter H, Lee M, Sipos B, Nakhai H, et al. (2010) Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 107: 13438-43.
35. De La OJ, Emerson LL, Goodman JL, Froebe SC, Illum BE, et al. (2008) Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A 105: 8907-12.
36. Wang YH, Li F, Luo B, Wang XH, Sun HC, et al. (2009) A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasia 56: 371-8.
37. Ji Q, Hao X, Zhang M, Tang W, Yang M, et al. (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4: e6816.
38. Bao B, Wang Z, Ali S, Kong D, Li Y, et al. (2011) Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 307: 26-36.
39. Ni X, Long J, Cen P, Chen L, Yang J, et al. (2011) Pancreatic cancer tumor initiating cells: the molecular regulation and therapeutic values. J Cell Mol Med [Epub ahead of print].
40. Wang Z, Ahmad A, Li Y, Azmi AS, Miele L, et al. (2011) Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res 31: 1105-13.
41. Takebe N, Harris PJ, Warren RQ, Ivy SP, (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8: 97-106.
42. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, et al. (2010) Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39: 425-35.
43. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, et al. (1986) Characterization of a new primary human pancreatic tumor line. Cancer Invest 4: 15-23.
44. Ikeda Y, Ezaki M, Hayashi I, Yasuda D, Nakayama K, et al. (1990) Establishment and characterization of human pancreatic cancer cell lines in tissue culture and in nude mice. Jpn J Cancer Res 81: 987-93.
45. Joo YE, Rew JS, Park CS, Kim SJ, (2002) Expression of E-cadherin, alpha- and beta-catenins in patients with pancreatic adenocarcinoma. Pancreatology 2: 129-37.
46. Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, et al. (2011) Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod Pathol 24: 1237-47.
47. Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, et al. (2009) gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 69: 573-82.
48. Niessen K, Fu Y, Chang L, Hoodless PA, McFadden D, et al. (2008) Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J Cell Biol 182: 315-25.
49. Hong SP, Wen J, Bang S, Park S, Song SY, (2009) CD-44 positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125: 2323-31.